Delivery Order SPE2DB22D1202-SPE2DB25FVKB8
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, with a contract ceiling value of $2,401.91. This is a firm fixed-price delivery order with an ultimate completion date of August 20, 2025, executed without a set-aside designation. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 16, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml) with a ceiling value of $2,079.82. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 17, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a $2,628.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml). This contract is non-set-aside and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $3,154.08 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 6, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement action typical of DLA's ongoing medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity, valued at $1,807.02. This is a firm fixed-price delivery order with no set-aside designation, indicating it was awarded through open competition. The order is scheduled for completion by June 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, with a firm fixed price ceiling value of $2,342.16. The contract is scheduled for completion by August 7, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designation, reflecting the contractor's established...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in a 60 mL quantity, with a ceiling value of $1,968.69. This is a firm fixed-price delivery order with an ultimate completion date of July 23, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, valued at $1,082.52 under a firm fixed-price contract. This delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 31, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a competitive delivery order valued at $1,971.30 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. The award, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed price transaction with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- The Defense Logistics Agency awarded a $2,919.39 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, with completion scheduled for September 5, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply framework with DLA. The pharmaceutical product will be delivered to the company's corporate...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVKB8Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, with a ceiling value of $2,110.28. This is a firm fixed price delivery order under a non-set-aside competitive award. The order is scheduled for completion by September 3, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract action, this delivery order is issued under a larger contract vehicle supporting the federal medical supply chain. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for the Defense Logistics Agency's medical procurement operations. The company maintains a significant Indefinite Delivery Contract with DLA Troop Support Medical valued at $999.99 billion through December 2026, which serves as the underlying vehicle for this and similar pharmaceutical delivery orders supporting military healthcare systems. The company's federal contract portfolio demonstrates extensive capability in delivering a comprehensive range of pharmaceutical products, medical supplies, and specialized healthcare commodities across multiple therapeutic domains to support Department of Defense and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 9/2/25 |